Last updated on November 2019

Stem Cell Ophthalmology Treatment Study II


Brief description of study

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Detailed Study Description

Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical and surgical practices. Retinal conditions may include degenerative, ischemic or physical damage ( examples may include macular degeneration, hereditary retinal dystrophies such as retinitis pigmentosa, stargardt, non-perfusion retinopathies, post retinal detachment. Optic Nerve conditions may include degenerative, ischemic or physical damage ( examples may include optic nerve damage from glaucoma, compression, ischemic optic neuropathy, optic atrophy ). Injections may include retrobulbar, subtenon, intravitreal, intraocular, subretinal and intravenous. Patients will be followed for 12 months with serial comprehensive eye examinations including relevant imaging and diagnostic ophthalmic testing.

Clinical Study Identifier: NCT03011541

Find a site near you

Start Over

The Healing Institute

Margate, FL United States
  Connect »

Euro-Arabian Hospital

Dubai, United Arab Emirates
  Connect »

MD Stem Cells

Westport, CT United States
  Connect »

MD Stem Cells

Coral Springs, FL United States
  Connect »